• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

The World Articles

Update The Latest Content Marketing Online

  • Home
  • About Us
  • Contact Us
  • Disclaimers
  • DMCA
  • Privacy Policy
  • Submit your story
  • Show Search
Hide Search
You are here: Home / SII seeks nod for phase 2/3 trials of Oxford’s Covid-19 vaccine candidate

SII seeks nod for phase 2/3 trials of Oxford’s Covid-19 vaccine candidate

· July 25, 2020 ·

        Serum Institute of India (SII), which has partnered with AstraZeneca for manufacturing the Oxford vaccine candidate for Covid-19, has sought permission from the Drugs Controller General of India (DCGI) for conducting phase 2/3 human clinical trials of the potential vaccine, highly-placed sources said on Saturday.The sources told PTI that the Pune-based drug firm submitted its application to the DCGI on Friday seeking permission for conducting the trials of ‘Covidshield’.“According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of ‘Covishield’ (Covid-19) in healthy Indian adults. The firm said that an around 1,600 participants of more than 18 years would be enrolled in the study,” a source said.Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the UK showed it has an acceptable safety profile and homologous boosting increased antibody responses, the source said.To introduce the vaccine, SII, the world’s largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca.On the partnership with AstraZeneca, Serum Institute of India CEO… Read full this story

  • It’s going to take a lot longer to make a COVID-19 vaccine than a treatment
  • 'No corona for me, hun': Demi Rose wears a face mask as she jets out of LA amid global COVID-19 outbreak
  • How will Europe tackle its growing COVID-19 threat?
  • Xinhua Headlines-Xi Focus: Xi stresses COVID-19 scientific research during Beijing inspection
  • A retrospect before denigrating China's COVID-19 handling
  • From patriotism to humanity: China leading the fight of the COVID-19
  • Coronavirus Vaccine 'Weeks' Away From Being Developed, Says Head of Israeli Science Research Institute
  • Drugmaker Moderna's coronavirus vaccine ready for human testing
  • Possible coronavirus treatment clinical trial begins in United States
  • Human trials of coronavirus vaccines could start next MONTH in the UK and US in global race to stop the killer disease which has infected 94,000 people worldwide
SII seeks nod for phase 2/3 trials of Oxford’s Covid-19 vaccine candidate have 328 words, post on www.hindustantimes.com at July 25, 2020. This is cached page on The World Articles. If you want remove this page, please contact us.

Primary Sidebar

RSS Recent Stories

  • High school student creates non-profit organisation to transform mental health amid COVID-19
  • High-tech farming needs investment and proper policies
  • Tân Sơn Nhất airport to serve 50m passengers a year by 2030
  • Nam Ô Reef, the green pearl of Đà Nẵng
  • Hi-tech investors flock to Đà Nẵng

Sponsored Links

  • How to Mute Your Google Smart Speaker or Display’s Microphone
  • How to Change Your TikTok Username
  • How to Create and Insert a Pyramid in Microsoft PowerPoint
  • What Does “RN” Mean, and How Do You Use It?
  • How to Add an Expiration Date to Emails in Gmail
  • How to Use Bangs in DuckDuckGo (to Search Other Websites)
Copyright © 2021 The World Articles. Power by Wordpress.